Yes_老虎社区_美港股上老虎

sharensim
2021-03-11

Yes

Should You Buy Moderna in March?

The stock is down big, but the company is coming off of an improved fourth quarter.

Should You Buy Moderna in March?

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":321324599,"tweetId":"321324599","gmtCreate":1615396604311,"gmtModify":1703488546348,"author":{"id":3577017083309122,"idStr":"3577017083309122","authorId":3577017083309122,"authorIdStr":"3577017083309122","name":"sharensim","avatar":"https://static.tigerbbs.com/0f4b1543300d240c4ec45ec276672815","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>Yes</body></html>","htmlText":"<html><head></head><body>Yes</body></html>","text":"Yes","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/321324599","repostId":2118367618,"repostType":4,"repost":{"id":"2118367618","kind":"news","pubTimestamp":1615382781,"share":"https://www.laohu8.com/m/news/2118367618?lang=&edition=full","pubTime":"2021-03-10 21:26","market":"us","language":"en","title":"Should You Buy Moderna in March?","url":"https://stock-news.laohu8.com/highlight/detail?id=2118367618","media":"Motley Fool","summary":"The stock is down big, but the company is coming off of an improved fourth quarter.","content":"The stock is down big, but the company is coming off of an improved fourth quarter.\nModerna&nbsp;(NASDAQ:MRNA) has been <a href=\"https://laohu8.com/S/AONE\">one</a> of the hottest stocks to buy over the past year, soaring more than 340% while theS&amp;P 500 has increased by just 30% during that time. The company's COVID-19 vaccine has put Moderna on the map with investors, sending its market cap from less than $10 billion to more than $52 billion. And if its CEO is right about COVID-19 being around forever, the vaccine could deliver recurring income for many years.\nHowever, Moderna's shares have been crashing over the past month despite a strong earnings report. Is March a good time to load up on the stock or should investors wait for more of a dip in price before investing in the company?\n<img src=\"https://static.tigerbbs.com/52d3762c89c18ae11c55b6954c91692b\" tg-width=\"700\" tg-height=\"466\">Image source: Getty Images.\nA lot depends on the future of COVID-19\nModerna's vaccine for COVID-19, mRNA-1273, has significant sales potential. The company expects the vaccine (which is also the first product Moderna's ever brought to market) will generate a staggering $18.4 billion in revenue in 2021. Those numbers would blow past Moderna's 2020 revenue, which at $803.4 million was already 13 times higher than 2019's top line of $60.2 million.\nWhether you think Moderna is a buy or not will likely come down to your outlook for the pandemic. If you anticipate that it will be around for the long term, then Moderna could certainly play a big role in containing the coronavirus. However, there is also the risk is that as more companies get the nod from the U.S. Food and Drug Administration (FDA) for their vaccines, there will also be more options for health officials to choose from, which will chip away at Moderna's market share.\nThe FDA granted&nbsp;Johnson &amp; Johnson's single-dose vaccine Emergency Use Authorization (EUA) on Feb. 27, making it the third vaccine that will now be available in the U.S., in addition to those from Moderna and&nbsp;Pfizer.AstraZeneca&nbsp;anticipates the FDA will issue its vaccine EUA in April while&nbsp;Novavax&nbsp;projects it will get the green light in May.\nBut Moderna's vaccine doesn't need to be <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the only two or three options to generate significant sales. Even if it generated half of that $18 billion on a recurring basis (perhaps through booster shots to treat variants of COVID-19), that along with other products in the pipeline could make it a formidable healthcare investment worth hanging on to.\nOne of the most promising vaccines in its pipeline today is mRNA-1647, which is for cytomegalovirus (CMV). On Feb. 25, when the company released its fourth-quarter earnings for the period ending Dec. 31, 2020, Moderna said its phase 3 study for the drug would begin \"soon.\"&nbsp;But even that vaccine, at its peak, could generate between $2 billion and $5 billion in sales for the company -- a small fraction of what Moderna looks to make from mRNA-1273.&nbsp;The company also has a vaccine for the Zika virus that is still in its early stages and that could be a \"several hundred-million-dollar annual peak sales opportunity.\"\nThe business isn'tentirely dependent on COVID-19, but the outlook for the pandemic definitely factors into the stock's hefty valuation; the worse it is, the more valuable Moderna becomes.\nModerna's stock is cheap(er) -- but is it low enough to buy?\nAlthough Moderna is coming off a strong fourth quarter, where sales came in at $570.7 million (compared to just $14.1 million in the prior-year period), its shares have fallen more than 30% in just the past month while the S&amp;P 500 is down just 1%. That is likely to do with a more favorable view of the pandemic and hope that things could soon be getting back to normal, especially now that President Joe Biden anticipates that by the end of May, there will have been enough vaccines available to inoculate all adults in the U.S.\nModerna's price today isn't anywhere near its 52-week lows or even close to $100 -- which it nearly fell to at the end of 2020. However, when looking at its forward price-to-sales (P/S) ratio, there does appear to be some great hidden value here:\n<img src=\"https://static.tigerbbs.com/2a409236ba53d13b1fe3d70f82010eb7\" tg-width=\"720\" tg-height=\"387\">MRNA PS Ratio (Forward) data by YCharts\nModerna compares well against the other COVID-19 stocks mentioned earlier as its future revenue from mRNA-1273 makes its valuation look attractive.\nShould you buy Moderna stock?\nWith a low P/S multiple and a good year ahead, Moderna's stock could potentially make for a solid investment. I wouldn't go so far as to say it is a greatlong-terminvestment, only because there are too many question marks surrounding COVID-19 in the years ahead. That includes whether mRNA-1273 will be needed beyond this year, if booster shots will be required to maintain immunity, and, ultimately, how much money the company might generate from pandemic-related revenue. Those are all variables that are unknowns right now and that makes it difficult to predict if Moderna is worth hanging on to over the long term.\nThe stock looks great, potentially for the next several months, or even the entire year. But beyond that, it becomes a riskier buy. So, while its share price is lower in March, long-term investors may still want to see the stock fall even further (perhaps below $100) before Moderna's stock is cheap enough that it makes up for some of that risk.","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Should You Buy Moderna in March?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShould You Buy Moderna in March?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-10 21:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/03/10/should-you-buy-moderna-in-march/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nThe stock is down big, but the company is coming off of an improved fourth quarter.\nModerna (NASDAQ:MRNA) has been one of the hottest stocks to buy over the past year, soaring more than 340% while ...\n\n<a href=\"https://www.fool.com/investing/2021/03/10/should-you-buy-moderna-in-march/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/03/10/should-you-buy-moderna-in-march/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2118367618","content_text":"The stock is down big, but the company is coming off of an improved fourth quarter.\nModerna (NASDAQ:MRNA) has been one of the hottest stocks to buy over the past year, soaring more than 340% while theS&P 500 has increased by just 30% during that time. The company's COVID-19 vaccine has put Moderna on the map with investors, sending its market cap from less than $10 billion to more than $52 billion. And if its CEO is right about COVID-19 being around forever, the vaccine could deliver recurring income for many years.\nHowever, Moderna's shares have been crashing over the past month despite a strong earnings report. Is March a good time to load up on the stock or should investors wait for more of a dip in price before investing in the company?\nImage source: Getty Images.\nA lot depends on the future of COVID-19\nModerna's vaccine for COVID-19, mRNA-1273, has significant sales potential. The company expects the vaccine (which is also the first product Moderna's ever brought to market) will generate a staggering $18.4 billion in revenue in 2021. Those numbers would blow past Moderna's 2020 revenue, which at $803.4 million was already 13 times higher than 2019's top line of $60.2 million.\nWhether you think Moderna is a buy or not will likely come down to your outlook for the pandemic. If you anticipate that it will be around for the long term, then Moderna could certainly play a big role in containing the coronavirus. However, there is also the risk is that as more companies get the nod from the U.S. Food and Drug Administration (FDA) for their vaccines, there will also be more options for health officials to choose from, which will chip away at Moderna's market share.\nThe FDA granted Johnson & Johnson's single-dose vaccine Emergency Use Authorization (EUA) on Feb. 27, making it the third vaccine that will now be available in the U.S., in addition to those from Moderna and Pfizer.AstraZeneca anticipates the FDA will issue its vaccine EUA in April while Novavax projects it will get the green light in May.\nBut Moderna's vaccine doesn't need to be one of the only two or three options to generate significant sales. Even if it generated half of that $18 billion on a recurring basis (perhaps through booster shots to treat variants of COVID-19), that along with other products in the pipeline could make it a formidable healthcare investment worth hanging on to.\nOne of the most promising vaccines in its pipeline today is mRNA-1647, which is for cytomegalovirus (CMV). On Feb. 25, when the company released its fourth-quarter earnings for the period ending Dec. 31, 2020, Moderna said its phase 3 study for the drug would begin \"soon.\" But even that vaccine, at its peak, could generate between $2 billion and $5 billion in sales for the company -- a small fraction of what Moderna looks to make from mRNA-1273. The company also has a vaccine for the Zika virus that is still in its early stages and that could be a \"several hundred-million-dollar annual peak sales opportunity.\"\nThe business isn'tentirely dependent on COVID-19, but the outlook for the pandemic definitely factors into the stock's hefty valuation; the worse it is, the more valuable Moderna becomes.\nModerna's stock is cheap(er) -- but is it low enough to buy?\nAlthough Moderna is coming off a strong fourth quarter, where sales came in at $570.7 million (compared to just $14.1 million in the prior-year period), its shares have fallen more than 30% in just the past month while the S&P 500 is down just 1%. That is likely to do with a more favorable view of the pandemic and hope that things could soon be getting back to normal, especially now that President Joe Biden anticipates that by the end of May, there will have been enough vaccines available to inoculate all adults in the U.S.\nModerna's price today isn't anywhere near its 52-week lows or even close to $100 -- which it nearly fell to at the end of 2020. However, when looking at its forward price-to-sales (P/S) ratio, there does appear to be some great hidden value here:\nMRNA PS Ratio (Forward) data by YCharts\nModerna compares well against the other COVID-19 stocks mentioned earlier as its future revenue from mRNA-1273 makes its valuation look attractive.\nShould you buy Moderna stock?\nWith a low P/S multiple and a good year ahead, Moderna's stock could potentially make for a solid investment. I wouldn't go so far as to say it is a greatlong-terminvestment, only because there are too many question marks surrounding COVID-19 in the years ahead. That includes whether mRNA-1273 will be needed beyond this year, if booster shots will be required to maintain immunity, and, ultimately, how much money the company might generate from pandemic-related revenue. Those are all variables that are unknowns right now and that makes it difficult to predict if Moderna is worth hanging on to over the long term.\nThe stock looks great, potentially for the next several months, or even the entire year. But beyond that, it becomes a riskier buy. So, while its share price is lower in March, long-term investors may still want to see the stock fall even further (perhaps below $100) before Moderna's stock is cheap enough that it makes up for some of that risk.","news_type":1},"isVote":1,"tweetType":1,"viewCount":306,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":3,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}